Конечностно-поясная прогрессирующая мышечная дистрофия типа 2А (кальпаинопатия)

Клиническая картина конечностно-поясной прогрессирующей мышечной дистрофии типа 2А (LGMD2A) обусловлена потерей функционально активного кальпаина-3 - специфической для скелетной мышечной ткани изоформы одного из белков семейства кальпаинов, вовлеченного в регуляцию различных тканевых процессов. Функция кальпаина-3 и патофизиологический механизм развития LGMD2A до конца не понятны. Рассматриваются особенности патогенеза, клинической картины и диагностики кальпаинопатии, а также обсуждается возможное применение трансгенов кальпаина-3 как специфической терапии данного заболевания. Представлены два клинических наблюдения.

1. Nadaj-Pakleza A.A., DorobekM., Nestorowicz, К. etal. Muscle pathology in 31 patients with calpain 3 gene mutations. Neural Neurochir Pol 2013; 47: 3: 214-222.

2. CottaA., Carvalho E., da-Cunha-Janior A.L. etal. Common recessive limb girdle muscular dystrophies differential diagnosis: why and how? Arq Neuropsiquiatr 2014; 72: 9: 721—734.

3. Angelini C, Nardetto L., Borsato C. et al. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 2010; 32: 41-46.

4. Fanin M., NascimbeniA.C, Fulizio L. et al. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 2003; 163: 1929-1936.

5. Roudaut C, Le Roy F., Suel L. et al. Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation 2013; 128: 10: 1094-1104.

6. Hashiguchi S., Adachi K, Inui T. et al. A clinicopatho-logical investigation of two autopsy cases of calpainopathy (LGMD2A). Brain Nerve 2014; 66: 9: 1097-1102.

7. Влодавец Д.В., Казаков Д. О. Диагностические возможности МРТ мышц при нервно-мышечных заболеваниях. Неврол журн 2014; 19: 3: 4-12. (Vlodavets D.V., Kaza-kov D.O. The diagnostic potential of muscle MRI in neuro-muscular diseases. Nevrol zhurn 2014; 19: 3: 4—12).

8. Suzuki K., Hata S., Kawabata Y, Sorimachi H. Structure, activation, and biology of calpain. Diabetes 2004; 53: Suppl 1:12—18.

9. Hauerslev S., Sveen M.L., Duno M. et al. Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies. BMC Musculoskelet Disord 2012; 13: 43.

10. KramerovaL, KudryashovaE., Tidball J.G., Spencer M/. Null mutation of calpain 3 (p94) in mice causes abnormal sarco-mere formation in vivo and in vitro. Hum Mol Genet 2004; 13: 1373-1388.

11. OjimaK, Kawabata Y, Nakao H. et al. Dynamic distribution of muscle-specific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. J Clin Invest 2010; 120:2672-2683.

12. Baghdiguian S., Martin M., Richard I. et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 1999; 5: 503-511.

13. Schmidt W.M., Uddin M.H., Dysek S. et al. DNA Damage, Somatic Aneuploidy, and Malignant Sarcoma Susceptibility in Muscular Dystrophies. PLoS Genet 2011; 7: 4: el002042."

14. BaumeisterS.K, Todorovic S., Mili -Rasi V. et al. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopa-thy. Neuromuscul Disord 2009; 19: 167-171.

15. Weinstock A., Green C, Cohen B.H. et al. Becker muscular dystrophy presenting as eosinophilic inflammatory myopathy in an infant. J Child Neurol 1997; 12: 146-147.

16. CantariniL., Volpi N., CarbottiP. et al. Eosinophilia-associat-ed muscle disorders: an immunohistological study with tissue localization of major basic protein in distinct clinicopatho-logical forms. J Clin Pathol 2009; 62: 442-447.

17. Schroder Т., Fuchss J., Schneider I. et al. Eosinophils in hereditary and inflammatory myopathies. Acta Myol 2013; 32: 3: 148-153.

18. Kramerova I., Kudryashova E., Wu B. et al. Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle. Hum Mol Genet 2009; 18: 17: 3194-3205.

19. Spencer M.J., GuyonJ.R., Sorimachi H. etal. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc Natl Acad Sci USA 2002; 99: 8874-8879.

20. Hayashi C, Ono Y, Doi N. et al. Multiple molecular interactions implicate the connectin/titin N2A region as a modulating scaffold for p94/calpain 3 activity in skeletal muscle. J Biol Chem2008; 283: 14801-14814.

21. Duguez S., Bartoli M., Richard I. Calpain 3: a key regulator of the sarcomere? FEBS J 2006; 273: 3427-3436.

22. Beckmann J.S., Spencer M. Calpain 3, the "gatekeeper" of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 2008; 18: 913-921.